BioFire Education
The BioFire BCID2 panel is a new technology being introduced in the UPMC Central PA microbiology laboratories. By having this new equipment, preliminary blood culture results will appear in the electronic medical record in a different timeline and format. Since this change is planned for March, we hope to use this February education session to educate our pharmacists on this new process and the appropriate response to the results. By providing this education in advance, we hope it will allow time to mitigate the more common questions and issues that will arise prior to the launch day.
In anticipation of the go-live of the BioFire® FilmArray® Blood Culture Identification 2 Panel (BCID2), this activity will help provide all pharmacists at UPMC in Central PA hospitals with the clinical and operational knowledge needed to respond to these positive blood cultures. The activity will review what pathogens and resistance patterns can be detected by the BCID2 and the timeline of expected results. In addition, it will cover the internal guideline recommendations as well as the literature supporting the use of this panel. Overall this activity aims to cover all baseline information relevant to the initiation of the BCID2 in order to optimize our response from an antimicrobial stewardship perspective.
Target Audience
Pharmacist
Learning Objectives
• Objective #1: Explain the purpose of Biofire
• Objective #2: Evaluate the expected timeline of Biofire results
• Objective #3: Select an appropriate initial treatment regimen based on the BCID2 Guidance
• Objective #4: Identify positive blood cultures that may represent potential contamination
Additional Information
Attachment | Size |
---|---|
CE Template with Audience Disclosure and SMS Credit.pptx | 409.5 KB |
The BioFire BCID2 panel is a new technology being introduced in the UPMC Central PA microbiology laboratories. By having this new equipment, preliminary blood culture results will appear in the electronic medical record in a different timeline and format. Since this change is planned for March, we hope to use this February education session to educate our pharmacists on this new process and the appropriate response to the results. By providing this education in advance, we hope it will allow time to mitigate the more common questions and issues that will arise prior to the launch day.
In anticipation of the go-live of the BioFire® FilmArray® Blood Culture Identification 2 Panel (BCID2), this activity will help provide all pharmacists at UPMC in Central PA hospitals with the clinical and operational knowledge needed to respond to these positive blood cultures. The activity will review what pathogens and resistance patterns can be detected by the BCID2 and the timeline of expected results. In addition, it will cover the internal guideline recommendations as well as the literature supporting the use of this panel. Overall this activity aims to cover all baseline information relevant to the initiation of the BCID2 in order to optimize our response from an antimicrobial stewardship perspective.
Elysia Burke, PharmD, BCIDP
Allison Hitchcock, PharmD, AAHIVP
In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Pharmacy (CPE)
This knowledge-based activity provides 1.0 contact hours of continuing pharmacy education credit.
Available Credit
- 1.00 ACPE PharmacyThe UPMC Center for Continuing Education in the Health Sciences is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a Provider of continuing pharmacy education.
- 1.00 Attendance